Form 4: Century Therapeutics SVP Sells Shares for Tax

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, sold 296 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Douglas Carr, SVP Finance & Operations at Century Therapeutics, Inc. (IPSC), reported a sale of common stock.
• The transaction occurred on August 4, 2025.
• A total of 296 shares were sold at a price of $0.534 per share.
• The sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• This sale was automatic and not at the discretion of Mr. Carr.
• Following this transaction, Mr. Carr beneficially owns 405,686 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax obligations related to RSU vesting, which is a common practice and does not indicate a change in management's view of the company's prospects.

Future Outlook

No forward-looking statements or guidance are provided.

Management Comments

• The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This is a company-specific insider transaction related to executive compensation and tax obligations, which is a common occurrence across industries and does not reflect broader industry trends.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale for tax purposes related to executive compensation.

Key Dates

Recommendation

The reported sale of shares by an executive is a non-discretionary transaction to cover tax obligations from RSU vesting, which is a common and expected event. It does not reflect a change in the company's fundamentals or management's confidence, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Century Therapeutics, IPSC, insider trading, Form 4, stock sale, executive compensation, restricted stock units, tax withholding